CIK 0001393434
- Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dugel Pravin −$233K Reporting owner sold <1% of stake
- Saroj Namrata −$232K Chief Business Officer sold 14% of stake
- Heier Jeffrey S. −$112K Chief Scientific Officer sold 4% of stake
- Kaiser Peter −$103K Chief Development Officer sold 5% of stake
- Anderman Todd −$87K Chief Legal Officer sold 8% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-10-11 | SUMMER ROAD LLC 10% owner | Purchase | +10,000 | $3.90 | $39K | 6,114,761 |
| 2022-10-10 | SUMMER ROAD LLC 10% owner | Purchase | +10,000 | $4.00 | $40K | 6,104,761 |
| 2022-09-29 | SUMMER ROAD LLC 10% owner | Purchase | +18,800 | $4.04 | $76K | 6,094,761 |
| 2022-09-28 | SUMMER ROAD LLC 10% owner | Purchase | +1,200 | $4.10 | $5K | 6,075,961 |
| 2022-09-27 | SUMMER ROAD LLC 10% owner | Purchase | +130,000 | $4.68 | $608K | 6,074,761 |
| 2022-07-14 | Ozden Rabia Gurses Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2022-07-01 | Ozden Rabia Gurses Chief Medical Officer | Grant or award | +6,667 | 52,223 | ||
| 2022-07-01 | Ozden Rabia Gurses Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-07-01 | Ozden Rabia Gurses Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 40,000 | ||
| 2022-06-16 | RAINES MERILEE Director | Grant or award | +8,933 | 8,933 | ||
| 2022-06-16 | RAINES MERILEE Director | Grant or award · Stock Option (Right to Buy) | +26,800 | 26,800 | ||
| 2022-06-16 | Williams Leslie J. Director | Grant or award | +8,933 | 13,433 | ||
| 2022-06-16 | Williams Leslie J. Director | Grant or award · Stock Option (Right to Buy) | +26,800 | 26,800 | ||
| 2022-06-16 | Warden Charles M Director | Grant or award | +8,933 | 48,464 | ||
| 2022-06-16 | Warden Charles M Director | Grant or award · Stock Option (Right to Buy) | +26,800 | 26,800 | ||
| 2022-06-16 | LINDSTROM RICHARD L MD Director | Grant or award | +8,933 | 108,402 | ||
| 2022-06-16 | LINDSTROM RICHARD L MD Director | Grant or award · Stock Option (Right to Buy) | +26,800 | 26,800 | ||
| 2022-06-16 | Hong Seung Suh Director | Grant or award | +8,933 | 8,933 | ||
| 2022-06-16 | Hong Seung Suh Director | Grant or award · Stock Option (Right to Buy) | +26,800 | 26,800 | ||
| 2022-06-16 | Heier Jeffrey S. Director | Grant or award | +8,933 | 47,933 |
Page 12 of 17 · 327 trades